Idexx Laboratories
IDXX
About: Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
Employees: 11,000
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
117% more first-time investments, than exits
New positions opened: 195 | Existing positions closed: 90
29% more capital invested
Capital invested by funds: $30.9B [Q1] → $39.8B (+$8.95B) [Q2]
22% more funds holding in top 10
Funds holding in top 10: 18 [Q1] → 22 (+4) [Q2]
8% more funds holding
Funds holding: 1,126 [Q1] → 1,215 (+89) [Q2]
1.62% more ownership
Funds ownership: 90.84% [Q1] → 92.46% (+1.62%) [Q2]
2% more repeat investments, than reductions
Existing positions increased: 420 | Existing positions reduced: 413
16% less call options, than puts
Call options by funds: $112M | Put options by funds: $133M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
|
Morgan Stanley
Erin Wright
|
$765
|
Overweight
Maintained
|
15 Aug 2025 |
|
Piper Sandler
David Westenberg
|
$700
|
Neutral
Maintained
|
11 Aug 2025 |
|
JP Morgan
Chris Schott
|
$675
|
Overweight
Maintained
|
4 Aug 2025 |
|
Leerink Partners
Daniel Clark
|
$600
|
Outperform
Maintained
|
17 Jul 2025 |
|
Stifel
Jonathan Block
|
$540
|
Hold
Maintained
|
2 Jul 2025 |
Financial journalist opinion
Based on 12 articles about IDXX published over the past 30 days
